|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The administration of Calcifediol in patients with COVID-19, will reduce the development of SARS and the worsening of the various phases of the syndrome. Reducing at least 25% in ICU admission and death from the process, reducing days of hospitalization, facilitating the recovery of the same, acting significantly and positively, in any of its phases throughout the natural history of illness. As a treatment with extensive experience of clinical use, safe, inexpensive, and potentially very effective, it will have a highly efficient cost-benefit impact on the prevention of SARS.
Description: Proportion of subjects who enter the Intensive Care UnitMeasure: Admission to Intensive Care Unit Time: At day 28.
Description: Proportion of subjects who die.Measure: Death Time: At day 28.
Description: Compare the time (in days) at discharge in newly hospitalized patients on non-invasive ventilation.Measure: Time from onset of symptoms to discharge of patients in conventional hospitalization Time: At day 28.
Description: In patients who, in the course of their evolution, required admission with mechanical ventilation in the ICU, time until admission to Intensive Care UnitMeasure: ICU - Time until admission Time: At day 28.
Description: In patients who, in the course of their evolution, required admission with mechanical ventilation in the ICU, time until mechanical ventilation is removed.Measure: ICU - Time mechanical ventilation is removed Time: At day 28.
Description: Evaluation of the inflammatory markers related to IL disease. Blood samples will be collected and assessed in order to evaluate interleukins related with the interleukin storm using immunological tests.Measure: Evaluation of the inflammatory markers related with the disease Time: At day 28.
Description: Evaluation of the Vitamin D metabolites.Measure: Vitamin D metabolites Time: At day 28.
Description: Compare the evolution in SatO2Measure: Evolution in SatO2 Time: At day 28.
Description: Compare the evolution in the Sat O2/FiO2 ratioMeasure: Evolution in the Sat O2/FiO2 ratio. Time: At day 28.
Description: Compare the evolution in the degree of dyspnea using the analog Borg scaleMeasure: Evolution in the degree of dyspnea Time: At day 28.
Description: Compare the evolution of radiological findings by simple radiology in the recruited subjects since their beginning in the trial until they end the trialMeasure: Evolution of the improvement of radiological findings by simple radiology Time: At day 28.
Description: Incidence of adverse events related to medication and its administration.Measure: Incidence of adverse events Time: At day 28.
Description: Incidence in the appearance of hemorrhagic or thrombotic phenomena.Measure: Appearance of hemorrhagic or thrombotic phenomena Time: At day 28.
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports